Hanall Biopharma (009420) — Capital Reinvestment Ratio
Hanall Biopharma (009420) has a Capital Reinvestment Ratio of 0.45x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩7.34 Billion) in capital expenditures (₩3.27 Billion). See Hanall Biopharma (009420) net asset quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hanall Biopharma Capital Reinvestment Ratio (2011–2024)
This chart tracks Hanall Biopharma's Capital Reinvestment Ratio across 10 annual periods. Check Hanall Biopharma cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Hanall Biopharma (2011–2024)
Year-by-year Capital Reinvestment Ratio for Hanall Biopharma from 2011 to 2024. For live market cap and broader valuation context, see market value of Hanall Biopharma.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.46x | ₩9.36 Billion | ₩23.07 Billion | ▲ +694.3% |
| 2023 | 0.31x | ₩29.64 Billion | ₩9.20 Billion | ▲ +176.3% |
| 2022 | 0.11x | ₩25.20 Billion | ₩2.83 Billion | ▼ -98.0% |
| 2021 | 5.48x | ₩839.87 Million | ₩4.61 Billion | ▲ +98.9% |
| 2020 | 2.76x | ₩929.29 Million | ₩2.56 Billion | ▲ +2561.8% |
| 2019 | 0.10x | ₩20.49 Billion | ₩2.12 Billion | ▲ +152.7% |
| 2017 | 0.04x | ₩42.14 Billion | ₩1.73 Billion | ▼ -96.0% |
| 2016 | 1.02x | ₩3.95 Billion | ₩4.03 Billion | ▲ +2.6% |
| 2012 | 0.99x | ₩2.20 Billion | ₩2.18 Billion | ▲ +1627.8% |
| 2011 | 0.06x | ₩7.41 Billion | ₩426.70 Million | — |